Table 1.

Hemodynamic Parameters in 20‐Week‐Old WT and dnNRSF‐Tg Mice Treated With or Without Ivabradine

	WT		dnNRSF‐Tg
	Control	Iva	Control	Iva
Blood pressure, mm Hg	105.1±3.7	100.4±6.6	100.2±1.1	98.3±3.5
Heart rate, /min	671±36.6	541±37.7	576±25.8	550±15.1
Echocardiographic data
LVDd, mm	3.3±0.18	3.13±0.19	4.11±0.14*	4.04±0.08*
LVDs, mm	1.65±0.13	1.4±0.12	2.87±0.13*	2.67±0.06*
IVST, mm	0.89±0.03	0.83±0.04	0.77±0.03	0.76±0.03
PWT, mm	0.93±0.04	0.87±0.03	0.82±0.04	0.79±0.04
FS, %	50.3±1.8	54.0±1.2	30.5±1.2*	33.6±1.3*
Hemodynamic data
LVSP, mm Hg	102.9±1.9	101.0±0.2	92.6±1.1	93.1±1.9
LVEDP, mm Hg	4.0±1.1	4.9±1.3	6.4±1.4	6.0±1.0
dP/dt, mm Hg/s	11 729.6±200.5	11 779.6±462.8	5754.7±626.5	6580.3±445.6
−dP/dt, mm Hg/s	5429.5±179.0	5584.1±462.8	4306.0±227.0	4500.8±474.6

Values are means±SEM. Numbers of mice tested for blood pressure and heart rate are 9 for untreated control WT, 5 for WT with ivabradine, 10 for untreated dnNRSF‐Tg, and 6 for dnNRSF‐Tg with ivabradine. Numbers of mice tested for echocardiography are 8 for untreated control WT, 3 for WT with ivabradine, 14 for untreated dnNRSF‐Tg, and 13 for dnNRSF‐Tg with ivabradine. Numbers of mice tested for hemodynamic analysis are 3 for each group. Kruskal–Wallis nonparametric ANOVA followed by the Bonferroni correction was used for analysis among the 4 groups. WT indicates wild type; dnNRSF‐Tg, dominant‐negative form of neuron‐restrictive silencer factor transgenic mice; Control, untreated control mice; Iva, mice treated with ivabradine; LVDd, left ventricular diastolic dimension; LVDs, left ventricular systolic dimension; IVST, interventricular septum thickness; PWT, posterior wall thickness; FS, fractional shortening; LVSP, left ventricular systolic pressure; LVEDP, left ventricular end diastolic pressure; dP/dt, first derivative of pressure; ANOVA, analysis of variance.

^*P<0.00833 vs untreated wild type.